Company intelligence / Profile preview

Innokeys

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Innokeys is a Singapore-based biotech company focused on oncology. It develops and commercializes innovations to address unmet needs, with its flagship asset being nimotuzumab, an anti-EGFR monoclonal antibody. Nimotuzumab is approved in over thirty countries for various solid tumors including head and neck, pancreatic, gastric, and cervical cancers, and the company coordinates its global late-stage clinical development and commercialization through partnerships.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

nimotuzumab

Commercial

Indications: Head and neck cancer, Nasopharyngeal cancer, Glioma, Esophageal cancer, Pancreatic cancer, Non-small cell lung cancer

Partnerships

InnoCIMABCIMAB

Beyond the preview

Go deeper on Innokeys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innokeys.

Explore the full profile